Abuse Deterrence: US Exclusivity Update May Ride User Fee Coattails
CDER's Woodcock suggests exclusivity rules outdated for abuse-deterrent technology development, and Rep. Griffith takes it to mean legal changes are needed.
You may also be interested in...
Industry exec suggests new packages need be merely no worse than the classic amber vial to gain a claim, but US FDA says packaging intended to fight abuse should be better.
Appropriations bill report includes language stating that it is 'imperative' the agency take all steps necessary to require opioid prescriber training.
US FDA says it expects to finalize guidance by November, but more research is needed with generic development questions lingering.